港股異動 | 泰格醫藥AH股齊升 半年內兩次回購股份用於股權激勵
格隆匯2月15日丨泰格醫藥(3347.HK)漲5.7%報74.45港元;泰格醫藥(300347.SZ)漲5.56%報98.34元。公司再度擬回購部分公司A股股份,回購金額不低於2.5億元且不超過5億元,回購價格不低於120元/股。此前泰格醫藥已實施過回購計劃。2021年8月至當年11月,公司完成第一次股份回購,總金額為5億元。日前,公司發佈業績預吿,預計2021年歸母淨利潤在26.2億元至30.3億元之間,同比增長50%至73%。預計歸母扣非淨利潤在11.33億元到13.24億元之間,同比增加60%到87%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.